Global Top 4 Companies Accounted for 94% of total Iron Chelation Drug market (QYResearch, 2021) | |
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high. People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas. There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition. The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin. The global key manufacturers of Iron Chelation Drug include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. In 2021, the global top four players had a share approximately 94.0% in terms of revenue. For more information, please contact the following e-mail address: Email: global@qyresearch.com Website: https://www.qyresearch.com | |
Target State: All States Target City : All Cities Last Update : 20 May 2024 4:17 PM Number of Views: 109 | Item Owner : April Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |